Health Network Laboratories (HNL), a provider of laboratory medicine services, has acquired Connective Tissue Gene Tests (CTGT) for an undisclosed price, in a deal that expands the buyer’s molecular diagnostic testing services into inherited genetic disorders.
CTGT provides more than 3,300 unique tests covering over 1,000 genes. The tests apply proprietary analytic methods, mutation database, and the company’s own technology, with the goal of delivering clinically actionable diagnostic information to healthcare providers worldwide.
“CTGT is an important and exciting addition to HNL's diagnostic service portfolio, allowing us to continue building on our heritage of innovation that provides best in class diagnostic services for the physicians and patients we serve,” Peter E. Fisher, MD, MBA, HNL’s president and CEO, said yesterday in a statement.
Added Jeff Wisotzkey, PhD, HCLD, CC, HNL’s Clinical Lab Director and Scientific Officer: “The acquisition of CTGT will complement HNL's comprehensive clinical genetic laboratory service programs in cancer, infectious disease, perinatal disease and pharmacogenomics by providing intellectual, bioinformatics and technical synergies amongst all the molecular genetic testing laboratories of HNL, and significantly enhance our capabilities in inherited disease diagnostic services.”
HNL has provided laboratory services for 35 years, more than 15 of which have been as an independent lab. According to its website, the company fields over 60,000 combined incoming and outgoing calls per month, employs more than 900 dedicated professionals and retains 25 board-certified pathologists and scientists. Patients access HNL’s services through its Patient Service Centers at more than 50 locations throughout central and eastern Pennsylvania and New Jersey.
Each year, HNL said, it generates more than 60 million clinical and anatomic pathology results for approximately 3 million patients and 12,000 healthcare providers.
Based in Allentown, PA, CTGT works with more than 10 hospital systems and has over 60 regional patient service centers.
CTGT, which is also based in Allentown, was founded in 2004 by James Hyland, MD, PhD, who is the company’s CEO and medical director; and Leena Ala-Kokko, MD, PhD, who is president and director of research, development and technology.
“HNL will benefit from CTGT’s innovative technologies and expertise in genetics. We are excited about HNL’s synergistic commitment to quality and customer service which has been so important to our clients,” the co-founders stated.
